Literature DB >> 17900302

Systemic and local interferon-gamma production following Mycobacterium ulcerans infection.

H S Schipper1, B Rutgers, M G Huitema, S N Etuaful, B D Westenbrink, P C Limburg, W Timens, T S van der Werf.   

Abstract

Buruli ulcer disease (BUD) is an emerging predominantly tropical disease caused by Mycobacterium ulcerans. The initial pre-ulcerative skin lesion often breaks down into an ulcer with undermined edges. Healing is common but may require considerable time, and scarring often results in functional limitations. Considerable evidence has now emerged that patients with early BUD cannot mount a sufficient protective T helper 1 (Th1) cell response to M. ulcerans, but uncertainty remains as to whether immune protection is restored over time. This study investigates the Th1 cell response of patients with various stages of BUD on mycobacterial antigens. We measured interferon (IFN)-gamma levels after ex vivo whole blood stimulation with tuberculin purified protein derivative (PPD), and compared the Th1 cell response of individuals with pre-ulcerative, ulcerative and healed BUD as well as healthy controls. Moreover, the systemic Th1 cell response was related to histopathological features in the various stages of surgically resected BUD lesions. We show that patients with ulcerative and healed BUD produce significantly higher IFN-gamma levels after mycobacterial ex vivo whole blood stimulation than healthy controls, and that patients with a granulomatous tissue response produce higher IFN-gamma levels than individuals without. We therefore suggest that the mounted Th1 cell response in ulcerative BUD patients might be related to their histopathological tissue response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17900302      PMCID: PMC2219368          DOI: 10.1111/j.1365-2249.2007.03506.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

Review 1.  Buruli ulcer: emerging from obscurity.

Authors:  Mark Wansbrough-Jones; Richard Phillips
Journal:  Lancet       Date:  2006-06-03       Impact factor: 79.321

2.  BCG vaccine effectiveness against Buruli ulcer: a case-control study in Benin.

Authors:  Fabienne Nackers; Michèle Dramaix; Roch Christian Johnson; Claude Zinsou; Annie Robert; Elisa DE Biurrun Bakedano; Judith R Glynn; Françoise Portaels; René Tonglet
Journal:  Am J Trop Med Hyg       Date:  2006-10       Impact factor: 2.345

3.  Effectiveness of excision of pre-ulcerative Buruli lesions in field situations in a rural district in Ghana.

Authors:  G Amofah; S Asamoah; C Afram-Gyening
Journal:  Trop Doct       Date:  1998-04       Impact factor: 0.731

4.  Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment.

Authors:  Edhyana Sahiratmadja; Bachti Alisjahbana; Tjitske de Boer; Iskandar Adnan; Anugrah Maya; Halim Danusantoso; Ronald H H Nelwan; Sangkot Marzuki; Jos W M van der Meer; Reinout van Crevel; Esther van de Vosse; Tom H M Ottenhoff
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

Review 5.  Mycobacterium ulcerans disease.

Authors:  Tjip S van der Werf; Ymkje Stienstra; R Christian Johnson; Richard Phillips; Ohene Adjei; Bernhard Fleischer; Mark H Wansbrough-Jones; Paul D R Johnson; Françoise Portaels; Winette T A van der Graaf; Kingsley Asiedu
Journal:  Bull World Health Organ       Date:  2005-11-10       Impact factor: 9.408

6.  Variability in 3' end of 16S rRNA sequence of Mycobacterium ulcerans is related to geographic origin of isolates.

Authors:  F Portaels; P A Fonteyene; H de Beenhouwer; P de Rijk; A Guédénon; J Hayman; M W Meyers
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

7.  Systemic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans.

Authors:  Dorothy Yeboah-Manu; Elisabetta Peduzzi; Ernestina Mensah-Quainoo; Adwoa Asante-Poku; David Ofori-Adjei; Gerd Pluschke; Claudia A Daubenberger
Journal:  J Leukoc Biol       Date:  2006-03-10       Impact factor: 4.962

8.  The local immune response in ulcerative lesions of Buruli disease.

Authors:  A E Kiszewski; E Becerril; L D Aguilar; I T A Kader; W Myers; F Portaels; R Hernàndez Pando
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

9.  Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis.

Authors:  R Phillips; C Horsfield; S Kuijper; S F Sarfo; J Obeng-Baah; S Etuaful; B Nyamekye; P Awuah; K M Nyarko; F Osei-Sarpong; S Lucas; A H J Kolk; M Wansbrough-Jones
Journal:  Clin Vaccine Immunol       Date:  2006-02

10.  Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response.

Authors:  R Phillips; C Horsfield; J Mangan; K Laing; S Etuaful; P Awuah; K Nyarko; F Osei-Sarpong; P Butcher; S Lucas; M Wansbrough-Jones
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

View more
  5 in total

1.  Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Authors:  Alexandra G Fraga; Andrea Cruz; Teresa G Martins; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Wayne M Meyers; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

2.  Serum levels of neopterin during antimicrobial treatment for Mycobacterium ulcerans infection.

Authors:  Janine de Zeeuw; Sridevi Duggirala; Willemien A Nienhuis; K Mohammed Abass; Wilson Tuah; Till F Omansen; Tjip S van der Werf; Ymkje Stienstra
Journal:  Am J Trop Med Hyg       Date:  2013-07-08       Impact factor: 2.345

3.  In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A Tool to Refine the Murine Buruli Ulcer Tail Model.

Authors:  Till F Omansen; Renee A Marcsisin; Brendon Y Chua; Weiguang Zeng; David C Jackson; Jessica L Porter; Ymkje Stienstra; Tjip S van der Werf; Timothy P Stinear
Journal:  Am J Trop Med Hyg       Date:  2019-12       Impact factor: 2.345

4.  Analysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression.

Authors:  Norman Nausch; Daniel Antwi-Berko; Yusif Mubarik; Kabiru Mohammed Abass; Wellington Owusu; Ellis Owusu-Dabo; Linda Batsa Debrah; Alexander Yaw Debrah; Marc Jacobsen; Richard O Phillips
Journal:  PLoS Negl Trop Dis       Date:  2017-02-27

5.  Mycolactone toxin induces an inflammatory response by targeting the IL-1β pathway: Mechanistic insight into Buruli ulcer pathophysiology.

Authors:  M Foulon; M Robbe-Saule; J Manry; L Esnault; Y Boucaud; A Alcaïs; M Malloci; M Fanton d'Andon; T Beauvais; N Labarriere; P Jeannin; L Abel; J P Saint-André; A Croué; Y Delneste; I G Boneca; L Marsollier; E Marion
Journal:  PLoS Pathog       Date:  2020-12-18       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.